Mon, Jul 28, 2014, 12:24 AM EDT - U.S. Markets open in 9 hrs 6 mins

Recent

% | $
Click the to save as a favorite.

Financial News From Zacks Small Cap Research

  • Advaxis (ADXS): Collaboration Could Lead to A Big License Zacks Small Cap Research - Thu, Jul 24, 2014 11:30 AM EDT

    By Grant Zeng, CFA NASDAQ:ADXS Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial Earlier this week (on July 22, 2014), Advaxis (NASDAQ:ADXS) and MedImmune, which is the global ...

  • In response to a notice from Nasdaq, Corporate Resource Services (CRRS) submitted a plan to regain listing compliance on June 23, 2014. Subsequently, on July 1, 2014, the company filed its FY 2013 10K. On July 9, 2014, CRRS received notice from Nasdaq that it was still non-compliant because it had not filed its 1Q FY …

  • CPXX: Update on CPX-351 and Technology Platform at Analyst Day Zacks Small Cap Research - Mon, Jul 21, 2014 12:30 PM EDT

    By Grant Zeng, CFA NASDAQ:CPXX On July 17, 2014, Celator Pharmaceuticals (NASDAQ:CPXX) updates on its lead candidate CPX-351 and CombiPlex (R)  technology platform at its Analyst Day meeting for analysts ...

  • IZEA: Early Mover in a Growth Space Zacks Small Cap Research - Fri, Jul 18, 2014 1:45 PM EDT

    IZEA (IZEA) facilitates advertising transactions within social media. Founded eight years ago, Florida-based IZEA operates a marketplace where advertisers pay creators who blog, vlog, tweet, pin or post about their products. It’s a digital form of product placement and endorsement using social media. IZEA provides an …

  • CYRX: DHL Deal A Great Fit For Both Parties Zacks Small Cap Research - Fri, Jul 18, 2014 9:18 AM EDT

    CryoPort Inc's (CYRX) deal with LifeConEx, DHL's cold-chain shipping division, was consummated after an apparent warm reception at DHL's Life Sciences & Healthcare Global Conference in China where CYRX presented last week.  Under the agreement (specific terms of which were not disclosed) CYRX will act as LifeConEx's sole …

  • NHC.TO: Northstar Healthcare pre-announces robust 2Q revenues; raise target Zacks Small Cap Research - Fri, Jul 18, 2014 9:00 AM EDT

    Earlier this week, Northstar Healthcare (NHC.TO) pre-announced consolidated revenue for the second quarter of 2014. Management estimates that second quarter revenue will be $15.1 million. As a result, we have raised our full-year revenue estimate to $73.2 million and raised our price target to $2.30, which is based on …

  • BLFS: New Manufacturing Contract A Clear Positive for BLFS Zacks Small Cap Research - Thu, Jul 17, 2014 1:00 PM EDT

    This morning (7/17/2014) BioLife Solutions (BLFS) announced that they signed a three year manufacturing contract with privately held Somahlution LLC, a Junipter, FL based biotech company.  Under the agreement, BLFS will manufacture Somahlution's DuraGraft, a solution used in the storage of veins harvested for use in heart …

  • ICAD: DermEbx/Radion Acquisition Looks Like a Real Win Zacks Small Cap Research - Thu, Jul 17, 2014 12:05 PM EDT

    The deal appears to be not only a seamless fit for iCAD in terms of potential synergies with their existing Therapy business, it will also almost immediately bolt on an additional $12M - $14M in recurring, relatively high margin revenue at what looks to be a very reasonable acquisition price.  The deal comes with additional …

  • MDGN: Trial / Development Timelines Remain On-Track Zacks Small Cap Research - Thu, Jul 17, 2014 12:00 PM EDT

    MDGN filed their 10-Q for the second quarter ending 6/30/2014.  Aside from recognizing more of the ~$2.2M (in total) OCS R&D grant during Q2 than what we had modeled, there were no surprises.  Net income and EPS came in at ($3.8)M and ($0.21), compared to our ($4.3)M and ($0.23) estimates.   MDGN continues preclinical …

  • AEMD Further De-Risks Balance Sheet Zacks Small Cap Research - Wed, Jul 16, 2014 3:15 PM EDT

    Aethlon Medical (AEMD) filed their 10-K for the fiscal year ending 3/31/2014.  Q4 revenue of $707k was well ahead of our $478k estimate as a result of AEMD recognizing more revenue from the year-3 contract during the quarter then we had anticipated.  In total, AEMD booked $658k in DARPA related revenue (reflecting the final …

  • SNGX: Soligenix Is Making Progress In Its Vaccine Programs Zacks Small Cap Research - Tue, Jul 15, 2014 10:30 AM EDT

    On July 9, 2014, Soligenix (SNGX) announced positive results from a preclinical study of the combination of RiVax™ and VeloThrax™. The combination induces protective antibodies for both ricin toxin and anthrax toxin exposure. Previously, Soligenix has demonstrated that each vaccine, when administered as a single vaccine, …

  • GRDH: Guardian 8 continues to lay the foundation for growth Zacks Small Cap Research - Mon, Jul 14, 2014 9:15 AM EDT

    Guardian 8 Holdings (GRDH) is the developer and manufacturer of the G8 Pro V2, a non-lethal security device designed for use in the professional security industry. We maintain our Outperform rating and price target of $0.90. During the first half of 2014, Guardian 8 Holdings established relationships with Securitas USA …

  • Yesterday, ENSERVCO (ENSV) provided an operational update concerning the second quarter and announced the second tranche of the company’s 2014 capital expenditure plan. Despite the operational disappointment, which is to some degree one-time in nature, the company’s organic capacity expansion continues with the announcement …

  • FMD: Third Quarter on Target: Maintaining 2014 and 2015 EPS Estimates Zacks Small Cap Research - Wed, Jul 9, 2014 7:30 PM EDT

    This compares to our third quarter loss estimate of $5.5 million, or a loss of $0.48 per diluted share. Importantly, this arrangement with SunTrust eliminates internally imposed balance sheet and concentration limits that had hurt loan growth, should improve revenue opportunities, and will provide for more efficient use …

  • CPKF: Maintaining 2014 EPS Estimate with Initial 2015 Estimate up 6% Zacks Small Cap Research - Thu, Jul 3, 2014 12:45 PM EDT

    We are maintaining our 2014 diluted EPS estimate for Chesapeake Financial Shares, Inc. (CPKF) at $1.70, even though first quarter results were a few cents shy of our estimate, as we expect this shortfall to be made up in the succeeding quarters for 2014. CPKF is predominantly a small business lender with 12 branch offices …

  • ZMS.V: Zecotek Files Q3 Financials Zacks Small Cap Research - Thu, Jul 3, 2014 9:30 AM EDT

    Zecotek Photonics (ZMS.V) (ZMSPF) filed their financials for their fiscal 2014 third quarter ending April 30, 2014.  Revenue continues to come in well below what we had been expecting and despite $2.0M worth of orders placed by Hamamatsu since July 2013, Zecotek has recorded just $90k in revenue since that time.  The company …

  • DEJ: Dejour Energy forms JV to accelerate development of Kokopelli Zacks Small Cap Research - Wed, Jul 2, 2014 9:30 AM EDT

    By Steven Ralston, CFA NYSE:DEJ TSX:DEJ.TO Dejour Energy (NYSE:DEJ) (TSX:DEJ.TO) entered into a joint venture with a private, US-based E&P company to develop Kokopelli. Dejour Energy received $3.75 million ...

  • FNRG: ForceField Energy joins the Russell Microcap Index Zacks Small Cap Research - Tue, Jul 1, 2014 2:45 PM EDT

    On June 27th, ForceField Energy (FNRG) joined the Russell Microcap Index as a result of the annual reconstitution process. Any portfolio manager of a passive or low tracking error microcap fund should be seriously considering the purchase of ForceField Energy, and if purchased, the position should be in strong hands for …

  • TBUFF: Tribute obtains $26M in private placement Zacks Small Cap Research - Fri, Jun 27, 2014 2:30 PM EDT

    By Anita Dushyanth OTC:TBUFF Tribute Pharma (OTC:TBUFF) announced on June 25 th 2014 that they are offering 37.3M units, with each issued unit representing one common share and one half warrant at a purchase ...

  • A new revenue growth platform for Rosetta (ROSG) is through collaboration with biotech/pharmaceutical companies to monetize its microRNA platform technologies. In June, Rosetta Genomics entered into an agreement with Moffitt Cancer Center to advance the development and commercialization of Rosetta's thyroid neoplasia assay. …

  • New Western Energy (NWTR) intends to expand the enhanced oil recovery from the current five spot well program to eight wells in the Winchester/Thomas lease located on the Burgess Formation. There are a number of shut in gas wells on the property.

  • Following the successful trials of S&W Seed's (SANW) dormant alfalfa seed in China the company has announced the first sale (and export) of its proprietary seeds to the Chinese market. China is the highest growth area in the world for the use of alfalfa as feed in the dairy market. The others are the introduction of high …

  • Labor Smart (LTNC): Branch Expansion Has Doubled Footprint This Year Zacks Small Cap Research - Thu, Jun 26, 2014 2:00 PM EDT

    Earlier today, Labor Smart (LTNC) announced that it has opened a new branch in Montgomery, Alabama. Labor Smart has continued to expand its footprint through organic new office openings and acquisitions. Management noted that it was optimistic about the construction sector in those two markets. That same month, Labor …

  • Neuralstem, Inc. (CUR): NSI-189: What You Need To Know Zacks Small Cap Research - Thu, Jun 26, 2014 10:15 AM EDT

    Neuralstem, Inc. (CUR) is developing NSI-189, a small molecule drug candidate for the treatment of major depressive disorder (MDD) and other psychiatric / cognitive impairment indications. The 24 patient Phase 1b study with NSI-189 was primarily a safety study, but secondary efficacy measures of depression, brain activity, …

  • SYRX: Initiating Coverage with a Buy Rating Zacks Small Cap Research - Wed, Jun 25, 2014 11:00 AM EDT

    By Marla Backer NASDAQ:SYRX Sysorex Global Holdings Corp. The last 15-months have been transformational for California based Sysorex Global Holdings Corp. (NASDAQ:SYRX) . The company has completed three ...

  • Arrowhead (ARWR): Current Price Does Not Reflect Value Zacks Small Cap Research - Wed, Jun 25, 2014 8:45 AM EDT

    By Grant Zeng, CFA NASDAQ:ARWR New Clinical Candidate ARC-AAT Announced Arrowhead Research Corporation (NASDAQ:ARWR)  is a clinical stage biotech company focused on RNAi therapeutics using its proprietary ...

  • PBIO: Recent Launch of Barozyme HT48 will Accelerate Revenue Growth Zacks Small Cap Research - Mon, Jun 23, 2014 9:15 AM EDT

    PBIO (PBIO) officially launched its much anticipated High Throughput PCT-based Barozyme HT48 for the enhanced preparation of proteins for mass spectrometry analysis at the American Society for Mass Spectrometry (ASMS) Annual Conference on Mass Spectrometry and Allied Topics held June 15-19, 2014 in Baltimore, Maryland. …

  • DEJ: Dejour Energy Increases WI in Woodrush to 99% Zacks Small Cap Research - Fri, Jun 20, 2014 9:00 AM EDT

    By Steven Ralston NYSE:DEJ TSX:DEJ After the close yesterday, Dejour Energy (NYSE:DEJ) (TSX:DEJ) announced the acquisition of an additional 24% working interest in the Woodrush oil & gas project for 9.6 ...

  • JAMN: Zacks maintains Outperform rating on Jammin Java’s FY1Q report Zacks Small Cap Research - Wed, Jun 18, 2014 9:25 AM EDT

    Marley Coffee (JAMN) reported financial results for the first fiscal quarter ending April 30, 2014. Marley Coffee again generated triple-digit, year-over-year revenue growth. Gross income declined 9.2% to $452,745 compared with $498,888 due to the gross profit margin compressing 3,972 basis points (bps) from 61.1% to …

  • PBSV: Results Remain Soft But Look For Growth in 2015 Zacks Small Cap Research - Tue, Jun 17, 2014 1:00 PM EDT

    Pharma-Bio Serv (PBSV) reported financial results for the fiscal second quarter ending April 30th.  For the second straight period both revenue and EPS missed our respective estimates, this is despite us making meaningful downward revisions to our model following Q1 results in late March.  PBSV noted that worldwide economic …

  • Grupo TMM (GTMAY): Positioning to Benefit from Energy Reforms Zacks Small Cap Research - Mon, Jun 16, 2014 2:30 PM EDT

    Grupo TMM (GTMAY) is positioning itself to benefit from the anticipated growth of maritime transportation that Mexico’s energy reforms are expected to fuel. In December 2013, Mexico passed measures to allow international companies to explore energy opportunities. Pemex’s goal is to attract international companies interested …

  • QCRH: First Quarter Is Better Than It First Appears Zacks Small Cap Research - Mon, Jun 16, 2014 1:30 PM EDT

    By Ann Heffron, CFA, CPA NASDAQ:QCRH QCRH’s 2014 first quarter diluted EPS of $0.40 was a couple of pennies shy of our $0.42 estimate. Despite this, it was a better quarter than we expected in several ...

  • FPMI: Additional Phase II Data Supports Utility of CardioPET Zacks Small Cap Research - Wed, Jun 11, 2014 1:00 PM EDT

    By Brian Marckx, CFA OBB:FMPI Quantitative Phase II Data Provides Additional Support of CardioPET Utility    FluoroPharma Inc. (OBB:FPMI) presented additional data from its ongoing phase II study of CardioPet ...

  • ITKG: Expected Launch of ElectriPlast a Likely Catalyst Zacks Small Cap Research - Tue, Jun 10, 2014 3:20 PM EDT

    Integral Technologies (ITKG)  has a new management team, new strategy, new product and new alliances with leading partners. Originally incorporated in 1996, Integral Technologies has restructured and repositioned itself to focus on a proprietary conducive plastic technology, ElectriPlast. Management believes ElectriPlast …

  • TBUFF: A Pharmaceutical Company With Strong Upside Potential Zacks Small Cap Research - Tue, Jun 10, 2014 11:00 AM EDT

    TBUFF’s strategy of in-licensing late-stage pharmaceutical products and marketing to under-served markets has substantially increased their revenue. Tribute Pharmaceuticals Inc. is a specialty pharmaceutical company headquartered in Canada with annual revenues of over $13M. Tribute has aggressively grown its pharmaceutical …

  • CRRS: Remain Positive on Business Trends Zacks Small Cap Research - Thu, Jun 5, 2014 3:00 PM EDT

    We remain enthusiastic about the growth prospects for Corporate Resource Services (CRRS), a staffing company that has launched an ambitious M&A strategy to complement its organic growth. In addition to its M&A initiatives, CRRS also has implemented initiatives to improve margins and profitability. CRRS has a nationwide …

  • GeneNews: Revenue from IDL Is Ramping Up Quickly Zacks Small Cap Research - Thu, Jun 5, 2014 12:00 PM EDT

    GeneNews launched ColonSentry(R) through IDL in the fourth quarter of 2013. First quarter of 2014 is the first full quarter of launch, including expanding IDL's lab capacity and increasing the size and scope of the sales activity focused on ColonSentry(R) as well as the rollout of new tests. Revenues from IDL for 1Q2014 …

  • Protalex PRTX-100 Looks To Have Anti-TNF Efficacy With Better Safety Profile Zacks Small Cap Research - Thu, Jun 5, 2014 7:30 AM EDT

    On June 3, 2014, Protalex (PRTX) announced preliminary unblinded results from cohorts 1-4 of the Phase 1b trial testing PRTX-100 as a treatment for rheumatoid arthritis (RA). The primary endpoint of this study is to assess the safety and tolerability of PRTX-100, with secondary objectives examining the effects of PRTX-100 …

  • Soligenix: Insiders Are Purchasing Shares Zacks Small Cap Research - Wed, Jun 4, 2014 7:00 AM EDT

    ·         In May, Soligenix insiders purchased total of 29,172 common shares ​·         In the last two years, Soligenix management and directors have been purchasing the company's shares, with no insiders selling any shares. ​We noticed that recently Soligenix (SNGX) management or directors are purchasing its shares. …

  • DelMar: On Track to Initiate Registrational Trial of VAL-083 for Brain Cancer in 2H14 Zacks Small Cap Research - Tue, Jun 3, 2014 10:00 AM EDT

    On May 31, 2014, DelMar (DMPI) presented interim clinical data from the Company's ongoing Phase I/II clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) at the ASCO conference. DelMar initiated the Phase I/II clinical trial of VAL-083 for the treatment of refractory glioblastoma multiforme (GBM) or …

  • LMD.V Revenue Jumps, Reflecting New Distribution Model Zacks Small Cap Research - Mon, Jun 2, 2014 2:00 PM EDT

    By Brian Marckx, CFA TSXV:LMD.V OTC:LEDIF Q1 2014 Results:   Revenue Jumps, Reflecting Benefits of Recent Change in Sales/Distribution Channels LED Medical (TSXV:LMD.V) (OTC:LEDIF) filed their Q1 2014 ...

  • Threshold (THLD): Update from ASCO Presentation Zacks Small Cap Research - Mon, Jun 2, 2014 10:00 AM EDT

    By Grant Zeng, CFA NASDAQ:THLD New Data Presented At ASCO for TH-302 for Multiple Myeloma ​ Background ​ In March 2012, Threshold (NASDAQ:THLD) initiated a Phase I/II (the 408 trial) open label clinical ...

  • ADXS: What Does the J&J Deal with Aduro Mean for Advaxis? Zacks Small Cap Research - Mon, Jun 2, 2014 7:15 AM EDT

    On May 29, 2014, privately held Aduro Biotech from Berkeley, California entered into an agreement with Janssen Biotech (a J&J company) granting the latter an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel live, attenuated, double-deleted Listeria …

  • As shown below revenue results were close to our forecasts. U-Haul truck and rental revenue is being driven by increasing capital expenditures that are not being matched by the competition. Rental revenue per truck increased by 4% and rental revenue per location increased by 15%. In 2015 the company intends to increase …

  • Threshold (THLD): Unleash the Power of Anti-Hypoxia for Cancer Treatment Zacks Small Cap Research - Fri, May 30, 2014 8:15 AM EDT

    Threshold Pharmaceuticals (THLD) is a late development stage biopharmaceutical company focused on hypoxia targeted therapy for cancer. Threshold’s key edge lies on its expertise in the tumor microenvironment. The Company is developing TH-302, a prodrug targeting tumor hypoxia, a common characteristic of the tumor mic …

  • AEMD: Cancer Gaining More Traction As Target for Hemopurifier Zacks Small Cap Research - Thu, May 29, 2014 7:30 AM EDT

    We have updated our report on Aethlon Medical (AEMD) for several recent developments.  See below for access to our full report on the company.  Earlier this month AEMD announced that they entered into a definitive agreement with DaVita Clinical Research (DCR), the CRO arm of dialysis services giant DaVita Healthcare, to …

  • NWTR forms operating entity for Kansas that could be expanded and generate revenue. Zacks Small Cap Research - Thu, May 29, 2014 7:01 AM EDT

    By Ian Gilson, PhD, CFA OTC:NWTR On May 28, 2014 the company announced the formation of an operating company, New Western Operating LLC (OTC:NWTR). This is a wholly owned entity which will operate the ...

  • Sorrento (SRNE): Balance Sheet Boosted by New Financing Zacks Small Cap Research - Wed, May 28, 2014 1:00 PM EDT

    By Grant Zeng, CFA NASDAQ:SRNE Sorrento Reports First Quarter Financials   Recently, Sorrento Therapeutics (NASDAQ:SRNE) reported its financials for the first quarter ending March 31, 2014. Total revenues ...

  • After reporting an initial case study showing both local and systemic anti-tumor effects of the DCVax-Direct treatment, on May 27, 2014, Northwest Biotherapeutics (NWBO) further provided a summary of initial data in its ongoing Phase I/II clinical trial of DCVax-Direct for inoperable solid tumors.  As a reminder, in June, …

  • Celator (CPXX): A Unique Drug Ratio Technology Company for Cancer Zacks Small Cap Research - Wed, May 28, 2014 8:00 AM EDT

    ​Based on the CombiPlex platform, the Company has developed a pipeline targeting various cancers. The Company’s pipeline includes two clinical stage products, CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia (AML), and CPX-1, a liposomal formulation of irinotecan:floxuridine, …

Next >>